Jump Financial LLC Raises Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Posted by on Aug 8th, 2023

Jump Financial LLC lifted its position in shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX – Free Report) by 88.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 122,091 shares of the company’s stock after acquiring an additional 57,196 shares during the period. Jump Financial LLC owned approximately 0.14% of Poseida Therapeutics worth $376,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its holdings in shares of Poseida Therapeutics by 7.0% in the 1st quarter. JPMorgan Chase & Co. now owns 318,676 shares of the company’s stock worth $1,428,000 after purchasing an additional 20,894 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Poseida Therapeutics by 48.5% in the first quarter. Dimensional Fund Advisors LP now owns 144,567 shares of the company’s stock worth $648,000 after acquiring an additional 47,233 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Poseida Therapeutics by 3.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 220,090 shares of the company’s stock valued at $987,000 after purchasing an additional 8,329 shares during the last quarter. Renaissance Technologies LLC lifted its position in Poseida Therapeutics by 456.5% during the first quarter. Renaissance Technologies LLC now owns 187,000 shares of the company’s stock valued at $838,000 after purchasing an additional 153,400 shares during the period. Finally, Silverarc Capital Management LLC boosted its holdings in Poseida Therapeutics by 2.0% in the first quarter. Silverarc Capital Management LLC now owns 239,696 shares of the company’s stock worth $1,074,000 after purchasing an additional 4,764 shares during the last quarter. 50.79% of the stock is currently owned by hedge funds and other institutional investors.

Poseida Therapeutics Stock Up 21.5 %

Shares of PSTX opened at $1.98 on Tuesday. The firm has a fifty day simple moving average of $2.04 and a two-hundred day simple moving average of $3.64. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.37. Poseida Therapeutics, Inc. has a 1-year low of $1.54 and a 1-year high of $8.82.

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 9th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). The firm had revenue of $10.34 million for the quarter, compared to analysts’ expectations of $10.00 million. Poseida Therapeutics had a negative net margin of 32.13% and a negative return on equity of 28.56%. On average, equities research analysts expect that Poseida Therapeutics, Inc. will post -1.7 EPS for the current year.

Poseida Therapeutics Profile

(Free Report)

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).

See Also

Institutional Ownership by Quarter for Poseida Therapeutics (NASDAQ:PSTX)

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.